Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$28.84 ▲ +0.06
(+0.21%)
MKT CAP: $2.98B • VOL: 2.00M
52W L $20 52W H $38
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$24
MEDIAN
$32
MEAN
$33
HIGH
$39
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BEAM TAPE
BEAM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $34.90 | $33.17 | 2025-02-14 | $26.24 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $36.34 | $34.03 | 2025-02-06 | $27.11 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $32.88 | $31.72 | 2025-01-29 | $27.69 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $29.42 | — | 2025-01-17 | $28.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $25.38 | $27.40 | 2025-01-09 | $25.67 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $34.32 | $29.99 | 2024-12-18 | $25.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $27.97 | $29.13 | 2024-12-04 | $26.82 | -4.3% | 48% | C |